Vanda Pharmaceuticals (VNDA) buy case: new drug approvals, pipeline, and growth catalysts vs. cash burn, losses, and neutral ...

Q1 2026 Management View “Revenue was $688 million, up 9% compared to the prior year, and adjusted EBITDA was $164 million, up 31% compared to last year. Both of these results were ahead of our ...

Q1 2026 earnings call: revenue and guidance, Casgevy royalties, DTx/SeQure growth drivers, and $10M buyback—read key takeaways.

Tuesday, May 12, 2026 at 8:30 a.m. ET. CALL PARTICIPANTS. Chief Executive Officer — Linda Findley; Chief Financial Officer — ...

ASX healthcare stocks have again fallen for the week ending May 8, as Morgans revise forecasts for several stocks following .

Verde AgriTech Ltd (TSX: NPK | OTCQX: VNPKF) ("Verde" or the "Company"), today reported its financial results for the period ended ...

Adjusted EBITDA was $4.1 million for the first quarter and above the midpoint of our guidance range of $2 million to $5 million, an increase of 88% over Q1 2025. Operating expenses were $84.1 million ...

Clinical Trial Share -- BioLife products are used in over 250 commercially sponsored cell and gene therapy (CGT) clinical ...

Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada1 Ninth consecutive quarter of ...

Riyadh: Saudi Aramco reported a sharp rise in first-quarter profit for 2026, beating analyst expectations as higher oil prices and increased crude sales offset geopolitical disruptions linked to ...

Average daily production increased 27% to 35,100 barrels of oil equivalent per day for the most recent quarter, with 32,000 ...

Learn how economic forecasting uses GDP, inflation, and key indicators to project future economic trends and inform business ...